KalVista Pharmaceuticals presented phase 2 data for KVD900 in a late-breaking session at European Academy of Allergy and Clinical Immunology (EAACI) Congress. The placebo-controlled, double-blind cross-over trial, the…
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.